Blockade of the VEGF pathway by VEGF or VEGF receptor inhibition improves immunotherapeutic responsiveness, partially by normalizing tumor vasculature; this facilitates infiltration of immune effector cells into tumors, and reprograms the immunosuppressive tumor microenvironment to an immunosupportive one12. The gene discussed is VEGFA; the disease is neoplasm.